Arora Shikha, Huffnagle Gary B
Immunology Graduate Program, Department of Internal Medicine, University of Michigan Medical School, Ann Arbor, MI 48109, USA.
Immunol Res. 2005;33(1):53-68. doi: 10.1385/IR:33:1:053.
Allergic bronchopulmonary mycosis (ABPM) is a devastating pulmonary disease that results from an aggressive allergic response to fungal colonization in the airways. Animal models using either fungal antigen or live infection reproduce most of the clinical features seen during ABPM in humans. Results from these studies have facilitated a detailed analysis of the key factors involved in the afferent as well as efferent phase of the disease. This review focuses on allergic bronchopulmonary disease caused by two different fungi (Aspergillus fumigatus and Cryptococcus neoformans): allergic bronchopulmonary aspergillosis and allergic bronchopulmonary cryptococcosis. Observations from both models underline the importance of initial innate immune responses and their translation into appropriate adaptive responses. In addition, data derived from knockout studies give emphasis to targeting cytokines and chemokines as a therapeutic strategy in the treatment of ABPM.
变应性支气管肺真菌病(ABPM)是一种严重的肺部疾病,由气道内真菌定植引发的强烈过敏反应所致。使用真菌抗原或活感染的动物模型可重现人类ABPM期间出现的大多数临床特征。这些研究结果有助于详细分析该疾病传入和传出阶段的关键因素。本综述聚焦于由两种不同真菌(烟曲霉和新型隐球菌)引起的变应性支气管肺疾病:变应性支气管肺曲霉病和变应性支气管肺隐球菌病。两种模型的观察结果都强调了初始固有免疫反应及其转化为适当适应性反应的重要性。此外,基因敲除研究得出的数据强调了将细胞因子和趋化因子作为治疗ABPM的治疗策略。